CHF263.10
1.00% today
SIX Swiss Exchange, Jun 24, 10:14 am CET
ISIN
CH0012032048
Symbol
ROG
Index
Sector
Industry

Roche Stock price

CHF260.50
+0.60 0.23% 1M
+9.50 3.78% 6M
+5.00 1.96% YTD
+5.10 2.00% 1Y
-80.50 23.61% 5Y
-11.90 4.37% 10Y
+101.30 63.63% 20Y
SIX Swiss Exchange, Closing price Mon, Jun 23 2025
+1.20 0.46%
ISIN
CH0012032048
Symbol
ROG
Index
Sector
Industry

Key metrics

Market capitalization CHF209.28b
Enterprise Value CHF226.62b
P/E (TTM) P/E ratio 25.24
EV/FCF (TTM) EV/FCF 15.02
EV/Sales (TTM) EV/Sales 3.75
P/S ratio (TTM) P/S ratio 3.46
P/B ratio (TTM) P/B ratio 6.52
Dividend yield 3.72%
Last dividend (FY24) CHF9.70
Revenue growth (TTM) Revenue growth 3.03%
Revenue (TTM) Revenue CHF60.50b
EBIT (operating result TTM) EBIT CHF20.09b
Free Cash Flow (TTM) Free Cash Flow CHF15.09b
Cash position CHF17.32b
EPS (TTM) EPS CHF10.32
P/E forward 14.48
P/S forward 3.31
EV/Sales forward 3.58
Show more

Create a Free Account to create an Roche alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Roche Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Roche forecast:

9x Buy
41%
9x Hold
41%
4x Sell
18%

Analyst Opinions

22 Analysts have issued a Roche forecast:

Buy
41%
Hold
41%
Sell
18%

Financial data from Roche

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
60,495 60,495
3% 3%
100%
- Direct Costs 15,783 15,783
1% 1%
26%
44,712 44,712
4% 4%
74%
- Selling and Administrative Expenses 13,758 13,758
2% 2%
23%
- Research and Development Expense 13,042 13,042
1% 1%
22%
20,438 20,438
8% 8%
34%
- Depreciation and Amortization 351 351
4% 4%
1%
EBIT (Operating Income) EBIT 20,087 20,087
8% 8%
33%
Net Profit 8,277 8,277
28% 28%
14%

In millions CHF.

Don't miss a Thing! We will send you all news about Roche directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roche Stock News

Neutral
Seeking Alpha
about 11 hours ago
Roche Holding AG (OTCQX:RHHBY) Virtual Hematology Investor Conference Call June 23, 2025 1:00 PM ET Company Participants Bruno Eschli - Head of Investor Relations Charles S. Fuchs - Global Head of Oncology & Hematology Drug Development—Genentech & Roche Daud Chaudry - Corporate Participant Conference Call Participants Colin Peter White - UBS Investment Bank, Research Division David Paul Evans -...
Neutral
Business Wire
4 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab-axgb) administered subcutaneously in combination with Polivy® (polatuzumab vedotin-piiq) demonstrated a clinically meaningful and statistically significant improvement in its prima...
Neutral
GlobeNewsWire
4 days ago
Basel, 20 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today results from the phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab) administered subcutaneously in combination with Polivy® (polatuzumab vedotin) demonstrated a clinically meaningful and statistically significant improvement in its primary endpoints of progression-free survival (PFS) and objective respon...
More Roche News

Company Profile

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Thomas Schinecker
Employees 103,249
Founded 1896
Website www.roche.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today